Answers are grounded in this paper and cite their sources.
Nondividing cancer cells are relatively resistant to chemotherapeutic drugs and environmental stress factors. Promoting cell cycle re‐entry of quiescent cancer cells is a potential strategy to enhance the cytotoxicity of agents that target cycling cells. It is therefore important to elucidate the mechanisms by which these cells are maintained in the quiescent state. The protein kinase dual specificity tyrosine phosphorylation‐regulated kinase 1B ( DYRK 1B) is overexpressed in a subset of cancers and maintains cellular quiescence by counteracting G 0 / G 1 –S phase transition. Specifically, DYRK 1B controls the S phase checkpoint by stabilizing the cyclin‐dependent kinase ( CDK ) inhibitor p27 Kip1 and inducing the degradation of cyclin D. DYRK 1B also stabilizes the DREAM complex that represses cell cycle gene expression in G 0 arrested cells. In addition, DYRK 1B enhances cell survival by upregulating antioxidant gene expression and reducing intracellular levels of reactive oxygen species ( ROS ). Substantial evidence indicates that depletion or inhibition of DYRK 1B drives cell cycle re‐entry and enhances apoptosis of those quiescent cancer cells with high expression of DYRK 1B. Furthermore, small molecule DYRK 1B inhibitors sensitize cells to the cytotoxic effects of anticancer drugs that target proliferating cells. These encouraging findings justify continued efforts to investigate the use of DYRK 1B inhibitors to disrupt the quiescent state and overturn chemoresistance of noncycling cancer cells.
No takes yet. Share an insight, caveat, or question.
Walter Becker (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: